MedTrace Logo

Effect of an Extract From the Wine Industry on Blood Pressure (HYPERGRAPES)

NCT04992936 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2023-03-16

No results posted yet for this study

Summary

By-products from the wine industry pose serious problems of management, both from an economic and environmental point of view. Although traditionally the use of by-products of the wine sector has been limited to the production of biogas and energy, or its use as animal feed or agricultural fertilizer, there is greater interest in the use of these by-products as a potential source of functional ingredients.

Cardiovascular diseases (CVD) are the main cause of mortality in Europe, with hypertension being one of the main CVD risk factors. It has been shown that lowering blood pressure through behavioral and pharmacological interventions significantly improves CVD. Currently, one of the most widely used pharmacological therapies to treat hypertension is based on the use of angiotensin converting enzyme (ACE) inhibitors such as Captopril or Enalapril. ACE plays a key role in arterial pressure regulation, catalyzing the production of angiotensin II, an octapeptide with potent vasoconstrictor activity. In addition, ACE catalyzes the inactivation of bradykinin, peptide with vasodilator activity. The evaluation of various potential by-products of the wine industry for the generation of functional ingredients showed that an extract from the wine industry presented beneficial effects on blood pressure in in vitro models as well as in vivo models using rats with hypertension.

Conditions

Interventions

DIETARY_SUPPLEMENT

Extract from the wine industry

The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.

DIETARY_SUPPLEMENT

Placebo

The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.

Sponsors & Collaborators

  • University Rovira i Virgili

    collaborator OTHER

  • Grandes Vinos y Viñedos S.A.

    collaborator UNKNOWN

  • Fundació Eurecat

    lead OTHER

Principal Investigators

  • Josep M Del Bas, PhD · UTNS (Eurecat-Reus)

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-08-26
Primary Completion
2022-06-22
Completion
2022-06-22

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04992936 on ClinicalTrials.gov